Fred Valeriote
Washington University in St. Louis
24 Papers
243 Citations
Fred Valeriote is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Leukemia & Cell killing. The author has an hindex of 13, co-authored 24 publications.
Chat about Author
Papers
•Journal Article
Synergistic Effect of Amphotericin B and 1,3-Bis(2-chloroethyl)-1-nitrosourea against a Transplantable AKR Leukemia
TL;DR: Long-term survivors of mice bearing a transplanted leukemia have been obtained following treatment with a combination of amphotericin B and 1, 3-bis(2-chloroethyl)1-nitrosourea, with about 75% of the survivors appeared healthy and had no detectable leukemic cells at the end of the 28-day period of observation.
69
Potentiation of Anticancer Agents by Amphotericin B
TL;DR: Most phase-specific agents showed little potentiation of cytotoxicity by AmB, but a dose-response effect was noted with both BCNU and adriamycin, with increased potentiation being observed with increasing doses of the anticancer agents.
35
•Journal Article
Potentiation of Anticancer Agent Cytotoxicity against Sensitive and Resistant AKR Leukemia by Amphotericin B
TL;DR: Amphotericin B was able to enhance the effects of actinomycin D (Act-D), adriamycin, and vincristine against AKR leukemia against resistant cells, although the degree of enhancement varied among these antitumor agents and decreased as drug resistance increased in the late-passage leukemia lines.
30
Cellular Quantitation of In Vivo Effects of 1-β-d-Arabinofuranosylcytosine on Leukemia L1210
TL;DR: A cellular model for the use of the cytidine analogue 1-beta-D-arabinofuranosylcytosine (ara-C) against L1210 leukemia in vivo was derived from dose- and time-survival studies and the extent of cell killing was as great as that produced by the best fractionation schedule.
27
•Journal Article
Cytosine arabinoside in experimental combination therapy.
Mark Edelstein,Fred Valeriote +1 more
TL;DR: Additional clinical studies are required to determine the role of combinations intraperitoneally, the necessity of intravenous sodium thiosulfate for use with intra peritoneal cisplatin, the activity of other agents, the optimum techniques to deliver intraperitonal drugs, and the appropriate clinical situations where intraperiatric therapy should be used in the overall management of ovarian cancer.
22